FindTrial
Sign In

A Blood-to-neural lineage reprogramming platform for personalized cell and brain organoid models to advance drug discovery for rare neurological disorders

A Blood-to-neural lineage reprogramming platform for personalized cell and brain organoid models to advance drug discovery for rare neurological disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099973
Enrollment
Unknown
Registered
2025-04-01
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis

Interventions

Observation group:None

Sponsors

The University of Hongkong - Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Clinically confirmed ALS patients who meet the 2008 Awaji-Shima diagnostic criteria; 2. Patients and their families who understand and agree to provide clinical data and peripheral blood samples.

Exclusion criteria

Exclusion criteria: 1.Children and adolescents under the age of 18; 2.Patients who have other similar neurological disorders such as Kennedy's disease, spinal muscular atrophy, and multifocal motor neuropathy in addition to ALS.

Design outcomes

Primary

MeasureTime frame
The cytopathological characteristics of motor neurons induced to differentiate;—

Countries

China

Contacts

Public ContactZeng Wenshuang

The University of Hongkong - Shenzhen Hospital

zengws@hku-szh.org+86 755 86913333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026